Alcon Inc Stock Price, News & Analysis

Alcon (ALC) has expanded the parameters of its TOTAL30 for Astigmatism contact lenses, now including a -2.75D cylinder offering. This monthly replacement Water Gradient toric contact lens, the first and only of its kind, maintains a 95% fit success rate and features PRECISION BALANCE 8|4 technology.

The expansion addresses the needs of astigmatic patients, who represent 47% of the patient population and are more prone to dryness and discomfort. The product includes Class 1 UV blocking against UVA and UVB rays and Blue-Violet Light filtration. The expanded parameters now cover 99% of astigmatic patients with a -3.00D cylinder or lower.

This development aligns with Canadian market preferences, where 61% of contact lens wearers choose reusable lenses. The product is now available across Canada, offering stability and month-long comfort at an affordable price.

Alcon (ALC) reported strong financial results for full-year 2024, with sales reaching $9.8 billion, up 5% (6% constant currency). The company achieved diluted EPS of $2.05 (up 5%) and core diluted EPS of $3.05 (up 11%).

Fourth-quarter 2024 performance showed sales of $2.5 billion, increasing 6% both on reported and constant currency basis. The Surgical segment generated $1.4 billion in Q4 sales, while Vision Care contributed $1.1 billion.

Key highlights include:

• Record $2.1 billion cash from operations
• Record free cash flow of $1.6 billion, up 120%
• Proposed dividend of CHF 0.28 per share
• New $750 million share repurchase authorization to offset equity incentive dilution

Alcon (SIX/NYSE: ALC) has launched SYSTANE PRO Preservative-Free (PF) in the U.S., its latest over-the-counter eye drop for dry eye relief. The product features a unique triple action, preservative-free formula that includes hyaluronate, nano-sized lipids, and HP-Guar, making it the longest-lasting eye drop in the SYSTANE portfolio.

The launch addresses a significant market need, as dry eye disease affects approximately 45.5 million people in the United States and 1.5 billion globally. SYSTANE PRO PF works by providing sustained hydration, restoring tear film stability, and protecting against further eye irritation. The product will be available in the U.S. starting this month, with expansion to additional markets planned for 2026.

SYSTANE is currently the #1 global consumer brand of artificial tears, and this new addition strengthens Alcon's position in the dry eye treatment market.

Alcon (ALC) announced the full U.S. commercial launch of Voyager DSLT, the first Direct Selective Laser Trabeculoplasty device for treating glaucoma and ocular hypertension. The automated device delivers 120 laser pulses without requiring a gonio lens, streamlining the treatment process for nearly 5 million Americans diagnosed with glaucoma.

Key features include an intuitive touchscreen interface and SureTrac eye-tracking technology for precise delivery. Clinical data shows that 62% of DSLT participants were medication-free at 12 months, and 92.5% would recommend the treatment to others. The device will be showcased at the 2025 American Glaucoma Society meeting in Washington, D.C.

This launch expands Alcon's glaucoma portfolio, which includes Hydrus Microstent, EX-PRESS Glaucoma Filtration Device, and pharmaceutical drops.

Alcon (SIX/NYSE: ALC) has announced that CEO David Endicott will present at the 2025 J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 4:30 p.m. PST. The presentation will be available via live webcast on the company's investor relations website.

Alcon, the global leader in eye care with a 75+ year heritage, serves over 260 million people annually across 140+ countries through their Surgical and Vision Care products. The company focuses on treating conditions including cataracts, glaucoma, retinal diseases, and refractive errors. With more than 25,000 associates, Alcon works to enhance quality of life through innovative products, partnerships with Eye Care Professionals, and programs advancing access to quality eye care.

Alcon (ALC) reported strong Q3 2024 results with sales of $2.4 billion, up 6% year-over-year. The company achieved diluted EPS of $0.53, a 29% increase, and core diluted EPS of $0.81, up 23%. Notable performance includes record free cash flow of $1.3 billion, up 119% in the first nine months. Surgical segment sales reached $1.3 billion (+5%), while Vision Care segment hit $1.1 billion (+7%). The company generated $1.6 billion in operating cash flows and updated its 2024 outlook, projecting net sales between $9.8-9.9 billion with core diluted EPS of $3.00-3.05.

Alcon (ALC) has launched PRECISION7, a revolutionary one-week replacement contact lens in the U.S. The lens features the world's first ACTIV-FLO System, providing 16 hours of comfort and precise vision through day 7. This innovation addresses affordability concerns, as over half of new patients opt for reusable lenses despite ECPs preferring daily disposables. PRECISION7 will be available through select ECPs immediately, with broader U.S. commercial availability in January 2025. The product launches with both sphere and toric lenses simultaneously, featuring a unique moisturizing system that combines water-loving agents and proprietary replenishing technology.

Alcon Singapore has been recognized as one of the 'Best Employers in Singapore' for three years (2021, 2023, and 2024), achieving second place in the Health Care Equipment & Services Industry category. The recognition comes from a comprehensive survey by The Straits Times, where associates anonymously evaluate their willingness to recommend their company. Alcon Singapore focuses on three key areas: Diversity & Inclusion, Social Impact and Sustainability, and Talent Development. The company implements various programs including the 'Women Supporting Women' initiative, community engagement through 'Alcon in Action', and the upgraded 'Development In Action' program for associate growth.

Alcon (SIX/NYSE: ALC) will showcase its latest innovations at the American Academy of Ophthalmology (AAO) 2024 annual meeting. Key highlights include:

• The Voyager DSLT, a new first-line laser therapy for glaucoma patients
• New handheld gas delivery systems, UNIFEYE and UNIPEXY, for retina surgeons
• Pivotal data presentation for AR-15512 (acoltremon 0.003%), a dry eye treatment candidate under FDA review

Alcon's booth #4008 will offer hands-on demonstrations of these technologies. The company emphasizes its focus on improving patient outcomes and enhancing surgical efficiency. New clinical data on Alcon's surgical products will also be presented at the conference.